IBI311
Sponsors
Innovent Biologics (Suzhou) Co. Ltd., Peking University People's Hospital, Shanghai Changzheng Hospital
Conditions
HealthyThyroid Associated OphthalmopathiesThyroid Associated OphthalmopathyThyroid Eye DiseaseThyroid Eye Disease, TED
Phase 1
Phase 2
Phase 3
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
CompletedNCT06126783
Start: 2023-10-20End: 2025-09-23Updated: 2026-05-01
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
CompletedNCT06269393
Start: 2024-01-01End: 2025-07-03Updated: 2026-03-24
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
RecruitingNCT07113262
Start: 2025-09-10End: 2027-12-31Target: 111Updated: 2025-11-17
Phase 4
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
RecruitingNCT07152340
Start: 2025-04-10End: 2030-05-01Target: 64Updated: 2025-09-03
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
RecruitingNCT07152366
Start: 2025-04-15End: 2035-04-15Target: 96Updated: 2025-09-03
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
RecruitingNCT07152392
Start: 2025-04-15End: 2035-04-15Target: 50Updated: 2025-09-03